Boston Scientific Debut's NIR ON Ranger Aug. 12 Following FDA Approval
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's U.S. launch on Aug. 12 of the NIR ON Ranger coronary stent opens up the flood gate for the firm's Scimed division to enter and immediately alter the competitive landscape of the estimated $1.3 bil. U.S. coronary stent market.